Skip to main content

Table 3 Baseline characteristics of studies in resistant P. aeruginosa

From: Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Author Year Design Country Case/Exposure Control/Comparator Total N Age cases (Yr) Age control (Yr) Male cases (%) Male controls (%)
Akhabue [41] 2011 CC, unmatched USA Cefepime-resistant P.aeruginosa Cefepime-susceptible P.aeruginosa 2529 Median:61 (total) Median:61 (total) 62 56.4
Fortaleza (b) [45] 2006 CC, matched Brazil Ceftazidime-resistant P.aeruginosa Control 165 median 38 median 44.5 72.7 62.7
Gasink [48] 2006 CC, unmatched USA Fluoroquinolone-resistant P.aeruginosa Fluoroquinolone-susceptible P.aeruginosa 847 56 62 NR NR
Harris [49] 2002 CC, unmatched USA Piperacillin-tazobactam-resistant P. aeruginosa Patients without Piperacillin-tazobactam-resistant P. aeruginosa 1315 53.4 49.7 42.5 39.4
Hsu [52] 2005 CC, unmatched USA Fluoroquinolone-resistant P.aeruginosa Fluoroquinolone-susceptible P.aeruginosa 177 73.8 68 43 49
Khayr [53] 2000 CC, unmatched USA Ciprofloxacin-resistant P.aeruginosa Ciprofloxacin-susceptible P.aeruginosa 94 Age > 65: 79% Age > 65: 79% 100 100
Trouillet [63] 2002 CC, unmatched France Piperacillin-resistant P. aeruginosa Piperacillin-susceptible P. aeruginosa 135 64.6 65.5 67.6 64.4
  1. CC case-control, NR not reported, YR year